Advertisement

Picture AB Sciex Berliner LCMSMS Symposium 2017 Middle 600x60px
Document › Details

MDS Inc.. (2/1/10). "Press Release: MDS Inc. Completes Divestiture of MDS Analytical Technologies". Toronto, ON.

Organisations Organisation MDS Inc.
  Group MDS (Group)
  Organisation 2 MDS Analytical Technologies
  Group Danaher (Group)
Products Product laboratory equipment and instruments
  Product 2 RADIOPHARMACEUTICAL
Index term Index term MDS–Danaher: mass spectrometer, 200909–201002 acquisition $650m in cash AB Sciex mass spectrometry business + former Molecular Devices Corp
Person Person West, Steve (MDS 201001– CEO bfore MDS Nordion 200701 President)
     


MDS Inc. (TSX: MDS; NYSE: MDZ), a leading provider of products and services to the global life sciences markets, today announced that it has completed the divestiture of its MDS Analytical Technologies business to Danaher Corporation (NYSE: DHR) for $650 million in cash.

"The divestiture of the MDS Analytical Technologies business marks a significant milestone in the Company's repositioning strategy and enables a substantial return of proceeds from the sale to shareholders," said Steve West, Chief Executive Officer, MDS Inc.

Proceeds from the Sale

MDS intends to return approximately $400 million to $450 million of the sale proceeds to shareholders by way of a share buyback through a Substantial Issuer Bid. The Company currently expects to initiate a Substantial Issuer Bid within the next 30 days.

Changes to Capital Structure

Concurrent with the closing of the sale, MDS has initiated actions to terminate its undrawn C$500 million revolving credit facility and to retire all outstanding Senior Unsecured Notes at a cost of approximately $223 million including principal, interest and make whole payments by February 3, 2010. The Company also deposited approximately $20 million in cash collateral to support existing letters of credit.

MDS Strategic Repositioning

Background materials pertaining to the new strategic direction for MDS Inc. can be found on MDS Inc.'s Website at http://www.mdsinc.com/strategic_repositioning_of_mds/index.asp.

About MDS

MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services that customers need for the development of drugs and the diagnosis and treatment of disease. MDS Inc. is a leading global provider of innovative technologies for use in medical imaging and radiotherapeutics, sterilization, and pharmaceutical contract research. MDS has more than 2,400 highly skilled people in nine countries. Find out more at www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.

   
Record changed: 2016-03-19

Advertisement

BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 600x60px

More documents for MDS (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 120x180px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px